Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Directors' Dealings

1 Jun 2018 08:01

RNS Number : 8749P
Accrol Group Holdings PLC
01 June 2018
 

1 June 2018

 

ACCROL GROUP HOLDINGS PLC(AIM: ACRL)

 

Directors' Dealings

 

 Accrol Group Holdings plc ("Accrol" or the "Company"), the leading independent tissue converter in the UK, is pleased to announce that certain directors of Accrol have, pursuant to the placing to raise £8.0 million (before expenses) described in the Company's announcement of 15 May 2018 titled "Proposed Placing to raise £8 million", in aggregate purchased 2,133,332 ordinary shares of £0.001 each ("Ordinary Shares") at a price of 15p per Ordinary Share as set out below.

 

 

 

 

Name

 

 

 

 Title

 

 

Number of Shares

 

 

Value of Shares

 

 

Resulting Shareholding

Percentage of Enlarged Share Capital

 

 

 

 

 

 

Daniel Wright

Executive Chairman

1,333,333

£200,000

1,748,501

0.96%

Gareth Jenkins

Chief Executive Officer

500,000

£75,000

600,000

0.33%

Martin Leitch

Interim Chief Financial Officer

266,666

£40,000

266,666

0.15%

Joanne Lake

Non-executive Director

33,333

£5,000

68,333

0.04%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

i) Dan Wright

ii) Gareth Jenkins

iii) Martin Leitch

iv) Joanne Lake

2

Reason for the notification

a)

Position/status

i) Executive Chairman

ii) Chief Executive Officer

iii) Chief Financial Officer

iv) Non-executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

15p

 

Volume(s)

i) 1,333,333

ii) 500,000

iii) 266,666

iv) 33,333

 

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

1 June 2017

f)

Place of the transaction

London Stock Exchange, AIM

 

Enquiries:

Zeus Capital Limited (Nominated Adviser & Broker)

 

Dan Bate / Andrew Jones

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000

 

 

Belvedere Communications Limited  

 

Cat Valentine (cvalentine@belvederepr.com)

Mob: +44 (0) 7715 769 078

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues as well as other tissue products to major retailers throughout the UK. 

 

Accrol operates from three sites:

 

· A manufacturing, storage and distribution facility in Blackburn;

· A facial tissue plant, also in Blackburn; and

· A manufacturing, storage and distribution facility in Leyland.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGMGFKZMDGRZM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.